ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Ovariectomy Without HRT Increases Death Rate

September 29, 2006

Clinical Trials: ECOG Says Results In Metastatic disease equivalent, Unlikely To change Over Time

April 16, 1999

“Realistic” Bypass Budget For 1983 asks $1.147Billion; Organ Site, Training, Control Would Get No Increases

September 18, 1981

CALG Loses Pediatrics Grant

July 20, 1979

NCI-Approved CTEP Trials For The Month of July

July 27, 2012

In Brief: Karmanos Institute Names Four To Faculty; $1.5M Donated To Kaplan Cancer Center

September 11, 1998